Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

A Study of How Ibuzatrelvir is Taken up Into the Blood of Healthy Adults After Taking Different Tablets of Ibuzatrelvir

← catalyst calendar

NCT07552779

Sponsored by Pfizer (industry) · PFE — their whole pipeline →.

Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Randomized · None · Basic science
Enrollment
17actual
Sites
1
Country
Belgium

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis
DateFiledBasisWhat it is
Start2026-04-13actualWhen the study began enrolling
Primary completion2026-06-03actualThe date the last participant is measured for the primary outcome — the readout window
Study completion2026-06-29actualThe whole study's end, after follow-up
First posted2026-04-27actualWhen this record first appeared on the registry
Results postedWhen the sponsor posted results to the registry
Record updated2026-07-28actualThe sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Conditions

  • Coronavirus Disease 2019
  • Coronavirus Disease 2019 (COVID-19)
  • COVID-19 (Coronavirus Disease 2019)
  • Upper Respiratory Tract Infections
  • Respiratory Tract Infection
  • Respiratory Tract Diseases
  • COVID-19
  • COVID-19 Infection
  • COVID-19 SARS-CoV-2 Infection
  • Pneumonia
  • Lung Diseases

Interventions

  • Drug: Ibuzatrelvir co-process API film coated tablet
  • Drug: Ibuzatrelvir filmcoated tablet

Primary outcomes

what the primary-completion date above is the date OF
Plasma ibuzatrelvir AUCinf (as data permit, otherwise AUClast) in the fasted state
measured Hour 0 pre-dose in each period and 0.5, 1, 2, 4, 6, 8, 12, 24, and 48 post-dose in each period
Plasma ibuzatrelvir AUCinf (as data permit, otherwise AUClast) in the fasted state
measured Hour 0 pre-dose in each period and 0.5, 1, 2, 4, 6, 8, 12, 24, and 48 post-dose in each period
Plasma ibuzatrelvir Cmax in the fasted state
measured Hour 0 pre-dose in each period and 0.5, 1, 2, 4, 6, 8, 12, 24, and 48 post-dose in each period
Plasma ibuzatrelvir Cmax in the fasted state
measured Hour 0 pre-dose in each period and 0.5, 1, 2, 4, 6, 8, 12, 24, and 48 post-dose in each period

Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed